Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (NASDAQ: CORT) has submitted a New Drug Application (NDA) to the FDA for relacorilant, its selective cortisol modulator, to treat platinum-resistant ovarian cancer. The submission is supported by positive data from Phase 3 ROSELLA and Phase 2 trials, where relacorilant combined with nab-paclitaxel showed improved progression-free and overall survival compared to nab-paclitaxel alone.
The drug demonstrated a favorable safety profile, with adverse events comparable to nab-paclitaxel monotherapy. This marks Corcept's second NDA before the FDA, alongside relacorilant for hypercortisolism. The company is preparing for immediate commercial availability following potential regulatory approval.
Corcept Therapeutics (NASDAQ: CORT) announced significant results from its CATALYST trial of Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes. The trial met its primary endpoint with patients receiving Korlym showing a 1.47% decrease in HbA1c compared to 0.15% in placebo group.
The study revealed that 24% of patients with difficult-to-control type 2 diabetes had hypercortisolism. Secondary endpoints were also met, with Korlym patients showing significant reductions in body weight (5.1 kg) and waist circumference (5.1 cm). Notably, patients receiving 900mg of Korlym demonstrated a 2.01% improvement in HbA1c.
The CATALYST trial, involving 1,057 patients across 36 U.S. sites, represents the largest and most rigorous study of its kind, with results simultaneously published in Diabetes Care.
Corcept Therapeutics (NASDAQ: CORT) has scheduled its first quarter financial results announcement and corporate update for May 5, 2025. The company will host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Key Conference Call Details:
- Participants must pre-register through a provided link
- Each registrant will receive a unique dial-in number and access PIN
- One PIN allows access for one caller
- A listen-only webcast option is available
- Call replay will be accessible through Corcept's website under Investors / Events tab
The Redwood City-based pharmaceutical company is maintaining transparency with investors through this scheduled financial disclosure and stakeholder communication event.
Corcept Therapeutics (NASDAQ: CORT) has announced it will present late-breaking data from its pivotal Phase 3 ROSELLA trial at the 2025 ASCO Annual Meeting. The study evaluates relacorilant plus nab-paclitaxel combination therapy versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer.
The presentation is scheduled for Monday, June 2, 2025, from 8:00 AM to 11:00 AM CDT as part of the Gynecologic Cancer Oral Abstract Session (Abstract Number: LBA5507). The ROSELLA trial is being conducted through a global collaboration with multiple oncology research groups, including GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG.
Corcept Therapeutics (NASDAQ: CORT) has published findings from the prevalence phase of its CATALYST trial in Diabetes Care journal, revealing that 24 percent of patients with difficult-to-control type 2 diabetes showed signs of hypercortisolism (Cushing's syndrome).
The study, the largest of its kind, screened 1,057 patients across 36 U.S. sites. All participants had hemoglobin A1c levels exceeding 7.5 percent despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. The screening was conducted using a standardized 1-mg dexamethasone suppression test (DST).
Part two of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, successfully met its primary endpoint of reduction in hemoglobin A1c. Complete results will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23, 2025.
Corcept Therapeutics (NASDAQ: CORT) has launched BELLA, a new Phase 2 trial evaluating the combination of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The single-arm, open-label trial aims to enroll 90 women across approximately 50 sites in North America, Europe, and Asia-Pacific.
The trial builds on the success of their pivotal Phase 3 ROSELLA trial, where the combination of relacorilant and nab-paclitaxel demonstrated improved progression-free and overall survival without increasing side effects. BELLA will investigate whether adding bevacizumab to this combination could provide an additional treatment option for patients.
Corcept Therapeutics (NASDAQ: CORT) announced positive results from its pivotal Phase 3 ROSELLA trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. The trial met its primary endpoint, demonstrating a 30% reduction in disease progression risk compared to nab-paclitaxel alone.
Key findings include:
- Median progression-free survival of 6.5 months vs 5.5 months for control group
- Median overall survival of 16.0 months vs 11.5 months for control group
- No new safety concerns identified
The trial enrolled 381 patients across multiple countries without requiring biomarker selection. Based on these results, Corcept plans to submit a New Drug Application (NDA) in Q3 and a Marketing Authorization Application (MAA) in Europe shortly after.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
